While these previous studies evaluated LRR risk by receptor status, this NMA has the advantage of solely quantifying LRR risk using the 21-gene expression assay in ER+/HER2− disease, highlighting the value of genomic testing in estimating LRR rates in this subgroup of breast carcinoma. Here, ERBB2 is linked to breast carcinoma.